Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VK-2019 |
Synonyms | |
Therapy Description |
VK-2019 inhibits Epstein-Barr nuclear antigen 1 (EBNA-1), which may block latent replication and proliferation, leading to the inhibition of EBV-positive tumor cell growth (J Clin Oncol 41, 2023 (suppl 16; abstr 6035)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VK-2019 | VK2019|VK 2019 | VK-2019 inhibits Epstein-Barr nuclear antigen 1 (EBNA-1), which may block latent replication and proliferation, leading to the inhibition of EBV-positive tumor cell growth (J Clin Oncol 41, 2023 (suppl 16; abstr 6035)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03682055 | Phase Ib/II | VK-2019 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | Terminated | USA | FRA | 3 |
NCT04925544 | Phase II | VK-2019 | Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV) Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV) Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | Recruiting | USA | 0 |